Full Year 2023 Investor Presentation
103
Investor presentation
Full year 2023
Novo NordiskⓇ
In phase 2, semaglutide showed significant improvements in
MASH resolution
Semaglutide showed resolution of MASH with no worsening of
fibrosis versus placebo in the phase 2 trial¹
Proportion of patients
100%
Semaglutide showed numerical improvements in fibrosis and fewer
patients had progression of fibrosis vs placebo in phase 2 trial¹
Proportion of patients with
improvements in fibrosis
100%
Proportion of patients with
progression of fibrosis
100%
80%
60%
40%
22.9%
20%
*
*
47.3%
46.9%*
80%
*
66.7%
80%
60%
60%
47.3%
47.8%
40%
35.9%
34.3%
40%
21.4%
20%
20%
10.8% 9.4%
*
5.8%
0%
0%
0%
Placebo
0.1 mg
0.2 mg
0.4 mg
Placebo 0.1 mg 0.2 mg 0.4 mg
Placebo 0.1 mg 0.2 mg 0.4 mg
semaglutide once-daily
semaglutide once-daily
semaglutide once-daily
¹Based on a complete case analysis, using people with an evaluable biopsy at end of trial
MASH: Metabolic dysfunction-associated steatohepatitis
Note: *statistically significant at 72 weeks (p<0.05 vs placebo); Analysis included patients with fibrosis stage 1, 2, or 3 at baseline. Data is from the semaglutide in MASH phase 2 trial.View entire presentation